menu
    • menu
    [{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Sequana Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nephrology","graph2":"Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Sequana Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sequana Medical \/ Sequana Medical"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Inapplicable"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Sequana Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sequana Medical \/ Sequana Medical","highestDevelopmentStatusID":"6","companyTruncated":"Sequana Medical \/ Sequana Medical"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequana Medical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sequana Medical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sequana Medical

    Menu

    Sequana Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical Confirms Dramatic Diuretic Response Improvement in MOJAVE Cohort Follow-Up

                            Details : DSR 2.0 is a disease-modifying heart failure drug therapy, which is currently being evaluated for the treatment of patients with diuretic-resistant heart failure.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical Announces DSMB Approval to Start MOJAVE Phase 1/2a Study of DSR® 2.0

                            Details : DSR 2.0 (Direct Sodium Removal) via peritoneal ultrafiltration using Infusate 2.0, is under phase 1/2 clinical trials for treatment of patients with diuretic-resistant heart failure.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 22, 2024

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin,Dapagliflozin,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical announces Positive Data from Non-Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 ...

                            Details : DSR 2.0 (icodextrin, dextrose, dapagliflozin) is an implant small molecule drug combination, currently being investigated for heart failure management.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 29, 2023

                            Lead Product(s) : Icodextrin,Dapagliflozin,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical Announces Initial Positive Data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for Treatment ...

                            Details : DSR 2.0 therapy (icodextrin) involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Icodextrin,Dextrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of I...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 28, 2023

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : Instituto Mexicano del Seguro Social

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2023

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : Instituto Mexicano del Seguro Social

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical Announces Positive Results From CHIHUAHUA, Phase 1 Clinical Trial of Second-Generation DSR Pro...

                            Details : DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Icodextrin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSR 1.0,Dapagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR Study, Reports Disease-Modifying Profile for Sho...

                            Details : Interim results from ten evaluable patients after completion of intensive DSR 1.0 (alfapump DSR Therapy) period demonstrated that DSR therapy safely, effectively and rapidly eliminated persistent congestion and restored euvolemia, resulting in mean weigh...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 19, 2022

                            Lead Product(s) : DSR 1.0,Dapagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 11, 2021

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Sequana Medical

                            Belgium arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dextrose

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Recipient : London Health Sciences Centre Research Institute (Lawson)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 26, 2020

                            Lead Product(s) : Dextrose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Recipient : London Health Sciences Centre Research Institute (Lawson)

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth